BioStem Technologies, Inc.
BSEM
$3.71
$0.102.77%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -49.13% | -13.89% | -31.84% | 2.71% | 56.12% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -49.13% | -13.89% | -31.84% | 2.71% | 56.12% |
| Cost of Revenue | -25.46% | -63.10% | -77.86% | -42.20% | 34.07% |
| Gross Profit | -52.88% | 5.54% | -20.52% | 12.96% | 60.31% |
| SG&A Expenses | 47.87% | 1,077.38% | 66.86% | 21.93% | 19.21% |
| Depreciation & Amortization | 499.19% | 228.43% | 3.10% | 6.04% | 3.39% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 28.93% | 338.87% | 25.01% | 18.46% | 36.80% |
| Operating Income | -201.21% | -146.66% | -102.21% | -26.18% | 115.42% |
| Income Before Tax | -203.00% | -146.19% | -101.28% | -21.53% | 161.90% |
| Income Tax Expenses | 289.41% | 1,658.47% | 1,345.96% | -169.98% | -170.19% |
| Earnings from Continuing Operations | -211.36% | -160.95% | -121.21% | 42.02% | 382.61% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -211.36% | -160.95% | -121.21% | 42.02% | 382.61% |
| EBIT | -201.21% | -146.66% | -102.21% | -26.18% | 115.42% |
| EBITDA | -194.52% | -144.14% | -101.50% | -25.85% | 113.25% |
| EPS Basic | -208.72% | -160.04% | -121.06% | 41.88% | 429.14% |
| Normalized Basic EPS | -197.67% | -145.34% | -101.38% | -25.11% | 129.60% |
| EPS Diluted | -258.45% | -186.23% | -136.12% | 29.47% | 540.49% |
| Normalized Diluted EPS | -240.91% | -165.29% | -112.09% | -33.68% | 128.59% |
| Average Basic Shares Outstanding | 1.94% | 1.64% | 1.92% | 3.94% | 8.04% |
| Average Diluted Shares Outstanding | -22.33% | -14.53% | 3.13% | 25.64% | 36.35% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |